P
PLIANT THERAPEUTICS INC
NASDAQ: PLRX (Pliant Therapeutics, Inc.)
Last update: 22 hours ago1.64
0.02 (1.23%)
| Previous Close | 1.62 |
| Open | 1.62 |
| Volume | 514,511 |
| Avg. Volume (3M) | 1,224,896 |
| Market Cap | 100,676,648 |
| Price / Sales | 3.07 |
| Price / Book | 0.460 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 23.40% |
| Current Ratio (MRQ) | 11.03 |
| Operating Cash Flow (TTM) | -174.10 M |
| Levered Free Cash Flow (TTM) | -112.84 M |
| Return on Assets (TTM) | -33.89% |
| Return on Equity (TTM) | -63.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Pliant Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 95.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tang Capital Management Llc | 30 Jun 2025 | 6,000,000 |
| Deep Track Capital, Lp | 30 Jun 2025 | 3,947,807 |
| Blue Owl Capital Holdings Lp | 30 Jun 2025 | 2,969,199 |
| Woodline Partners Lp | 30 Jun 2025 | 2,348,526 |
| Madison Avenue Partners, Lp | 30 Jun 2025 | 2,230,012 |
| Trv Gp Iv, Llc | 30 Jun 2025 | 2,132,867 |
| Redmile Group, Llc | 30 Jun 2025 | 1,632,577 |
| Acadian Asset Management Llc | 30 Jun 2025 | 1,630,413 |
| Peapod Lane Capital Llc | 30 Jun 2025 | 893,730 |
| 52 Weeks Range | ||
| Median | 4.00 (143.90%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 08 Aug 2025 | 4.00 (143.90%) | Buy | 1.66 |
| Date | Type | Details |
|---|---|---|
| 07 Aug 2025 | Announcement | Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results |
| 27 Jun 2025 | Announcement | Pliant Therapeutics Provides Update on BEACON-IPF |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |